Susquehanna International Group’s Aprea Therapeutics APRE Stock Holding History

Susquehanna International Group’s Portfolio APRE Stock Details APRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$9.93K	Buy	+13,018	New	+$10.2K	﹤0.01%	12940
2024 Q3	–	Sell	-10,119	Closed	-$41.2K	–	11897
2024 Q2	$41.2K	Buy	+10,119	New	+$52.2K	﹤0.01%	11485
2023 Q1	–	Sell	-668	Closed	-$4.93K	–	12510
2022 Q4	$4.3K	Sell	668 -215	-24%	-$2.27K	﹤0.01%	12065
2022 Q3	$11K	Sell	883 -2,215	-71%	-$39.3K	﹤0.01%	12749
2022 Q2	$46K	Sell	3,098 -2,470	-44%	-$56.9K	﹤0.01%	12022
2022 Q1	$208K	Buy	5,568 +2,279	+69%	+$93.4K	﹤0.01%	11146
2021 Q4	$189K	Sell	3,289 -6,694	-67%	-$591K	﹤0.01%	11509
2021 Q3	$1.02M	Buy	9,983 +6,330	+173%	+$575K	﹤0.01%	7511
2021 Q2	$357K	Buy	+3,653	New	+$338K	﹤0.01%	10392

Other funds holding APRE

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SRL

Scientech Research LLC Jersey City, New Jersey $120M AUM 73.62% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Susquehanna International Group's APRE Position: Q1 2026 in Review

Susquehanna International Group opened a new position in Aprea Therapeutics (APRE) in Q1 2026: 13,018 shares worth $9.93K. The stake represents ﹤0.01% of the portfolio and ranks #12940 among its holdings. This is a return to the name: Susquehanna International Group previously reported a position in APRE as recently as Q2 2024.

Susquehanna International Group first reported a position in APRE in Q2 2021 and has held it in 9 quarters since. The position peaked at $1.02M in Q3 2021. 22 funds tracked by Wall St. Rank hold APRE as of Q1 2026.

Susquehanna International Group held 13,018 shares of Aprea Therapeutics worth $9.93K as of Q1 2026.
Aprea Therapeutics was a new Susquehanna International Group position in Q1 2026.
Aprea Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #12940 holding.
Susquehanna International Group first reported a position in Aprea Therapeutics in Q2 2021 and has held it in 9 quarters since.
Susquehanna International Group's Aprea Therapeutics position peaked at $1.02M in Q3 2021.
22 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.